NBIX Neurocrine Biosciences, Inc.

+0.9  (2.09%)
Previous Close 43.15
Open 42.90
Price To book 11.90
Market Cap 3.83B
Shares 86,874,000
Volume 617,977
Short Ratio 3.01
Av. Daily Volume 1,099,270

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 planned for 2017.
Essential Tremor
NDA filing planned - license agreement with BIAL announced February 9, 2017.
Parkinson's disease
Phase 2 data due April 2017.
Tourette syndrome - juvenile
Phase 2 data released January 18, 2017 did not meet primary endpoint.
Tourette syndrome - adults
Phase 3 initiated by partner Abbvie in January 2016. Data due 4Q 2017.
Uterine Fibroids
First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA Filing due 3Q 2017.
PDUFA date under priority review April 11, 2017. Announced January 5, 2017 that the Advisory Committee Meeting originally scheduled for February 16, 2016 has been cancelled.
Tardive dyskinesia

Latest News

  2. Neurocrine Biosciences, Inc. :NBIX-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017
  3. NBIX: Acquires North American Rights to ONGENTYS® For the Treatment of Parkinson’s Disease
  4. Edited Transcript of NBIX earnings conference call or presentation 14-Feb-17 10:00pm GMT
  5. NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
  6. Neurocrine reports 4Q loss
  7. Neurocrine reports 4Q loss
  8. Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017
  9. Q4 2016 Neurocrine Biosciences Inc Earnings Release - After Market Close
  10. NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Pri
  11. Neurocrine Inks $145 Million Parkinson's Drug Deal
  12. Neurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone
  13. Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results
  14. Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : February 1, 2017
  15. Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen
  16. Neurocrine Biosci upgraded by Oppenheimer
  17. NBIX: Phase 2 Study of INGREZZA™ in Adults with Tourette Syndrome Fails to Hit Primary Endpoint
  18. After hours buzz: CSX, UAL, GIMO & more